Comparing the Prognosis of Non‐Small Cell Lung Cancer Patients Who Did Not Undergo Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy: A Retrospective Study

Key Points

• This research aims to evaluate the prognosis of non-small cell lung cancer (NSCLC) patients who did not undergo surgery after neoadjuvant chemotherapy and immunotherapy.
• Conducted a retrospective analysis of NSCLC patients who did not have surgery after neoadjuvant chemotherapy plus immunotherapy.
• Compared outcomes such as overall survival (OS) and progression-free survival (PFS) between two groups: those receiving radiotherapy (RTG) and those not receiving it (nRTG).
• Analyzed the impact of PET/CT evaluations on treatment decisions.
• No significant differences in overall survival or progression-free survival were found between the RTG and nRTG groups.
• Radiotherapy remains a key therapeutic option for patients without PET/CT evaluation.
• For patients with PET/CT SUVmax ≤ 4, radiotherapy can be safely omitted, while those with SUVmax > 4 require radiotherapy as part of their treatment strategy.